Glucophage, Avandamet(metformin)
/ Metformin, Actoplus Met, Avandamet, Competact, Ebymect, Efficib, Eucreas, Fortamet, Glumetza, Icandra, Invokamet, Janumet, Jentadueto, Kazano, Komboglyze, Metformin, Metformin /, Prandimet, Qternmet, Qtrilmet, Ristfor, Segluromet, Sitagliptin / Metformin, Synjardy, Trijardy, Velmetia, Vipdomet, Vokanamet, Xigduo, Zituvimet, Zomarist (metformin) is a small molecule pharmaceutical. Metformin was first approved as Glucophage on 1995-03-03. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. It is known to target multidrug and toxin extrusion protein 1 and multidrug and toxin extrusion protein 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Glumetza, Metformin (discontinued: Fortamet, Glucophage, Metformin, Riomet)
CombinationsActoplus met, Glipizide metformin, Glyburide metformin, Invokamet, Janumet, Jentadueto, Kazano, Linagliptin metformin, Pioglitazone metformin, Saxagliptin metformin, Segluromet, Synjardy, Trijardy, Xigduo, Zituvimet (discontinued: Actoplus met, Avandamet, Empagliflozin metformin, Glipizide metformin, Glucovance, Glyburide metformin, Kombiglyze, Metaglip, Pioglitazone metformin, Prandimet, Qternmet, Repaglinide metformin, Rosiglitazone metformin, Saxagliptin metformin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Metformin hydrochloride
Metformin hydrochloride
+
Pioglitazone hydrochloride
Canagliflozin
+
Metformin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| INVOKAMET XR | Johnson & Johnson | N-205879 RX | 2016-09-20 | 4 products, RLD, RS |
| INVOKAMET | Johnson & Johnson | N-204353 RX | 2014-08-08 | 4 products, RLD, RS |
Metformin hydrochloride
+
Sitagliptin phosphate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| JANUMET XR | Merck & Co | N-202270 RX | 2012-02-02 | 3 products, RLD, RS |
| JANUMET | Merck & Co | N-022044 RX | 2007-03-30 | 2 products, RLD, RS |
Linagliptin
+
Metformin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| JENTADUETO XR | Boehringer Ingelheim | N-208026 RX | 2016-05-27 | 2 products, RLD, RS |
| JENTADUETO | Boehringer Ingelheim | N-201281 RX | 2012-01-30 | 3 products, RLD, RS |
Metformin hydrochloride
+
Saxagliptin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KOMBIGLYZE XR | AstraZeneca | N-200678 DISCN | 2010-11-05 | 3 products, RLD |
Hide discontinued
Dapagliflozin
+
Metformin hydrochloride
+
Saxagliptin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| QTERNMET XR | AstraZeneca | N-210874 DISCN | 2019-05-02 | 4 products, RLD |
Hide discontinued
Empagliflozin
+
Metformin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SYNJARDY XR | Boehringer Ingelheim | N-208658 RX | 2016-12-09 | 4 products, RLD, RS |
| SYNJARDY | Boehringer Ingelheim | N-206111 RX | 2015-08-26 | 4 products, RLD, RS |
Empagliflozin
+
Linagliptin
+
Metformin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRIJARDY XR | Boehringer Ingelheim | N-212614 RX | 2020-01-27 | 4 products, RLD, RS |
Dapagliflozin
+
Metformin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| XIGDUO XR | AstraZeneca | N-205649 RX | 2014-10-29 | 5 products, RLD, RS |
Metformin hydrochloride
+
Sitagliptin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZITUVIMET XR | Zydus Therapeutics | N-216778 RX | 2024-07-18 | 3 products, RLD, RS |
| ZITUVIMET | Zydus Therapeutics | N-216743 RX | 2023-11-03 | 2 products, RLD, RS |
Metformin hydrochloride
+
Rosiglitazone maleate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AVANDAMET | SB Pharmco | N-021410 DISCN | 2002-10-10 | 5 products, RLD |
Hide discontinued
Glyburide
+
Metformin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| GLUCOVANCE | Bristol Myers Squibb | N-021178 DISCN | 2000-07-31 | 3 products, RLD |
Hide discontinued
Alogliptin benzoate
+
Metformin hydrochloride
Glipizide
+
Metformin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| METAGLIP | Bristol Myers Squibb | N-021460 DISCN | 2002-10-21 | 3 products, RLD |
Hide discontinued
Metformin hydrochloride
+
Repaglinide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PRANDIMET | Novo Nordisk | N-022386 DISCN | 2008-06-23 | 2 products, RLD |
Hide discontinued
Ertugliflozin
+
Metformin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SEGLUROMET | Merck & Co | N-209806 RX | 2017-12-19 | 4 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| actoplus met | New Drug Application | 2025-03-27 |
| alogliptin and metformin hydrochloride | NDA authorized generic | 2025-04-11 |
| appformin | unapproved drug other | 2011-08-08 |
| appformin-d | unapproved drug other | 2011-08-08 |
| avandamet | New Drug Application | 2012-08-30 |
| dapagliflozin and metformin hydrochloride | NDA authorized generic | 2024-12-20 |
| fortamet | New Drug Application | 2010-03-15 |
| glipizide and metformin hydrochloride | ANDA | 2018-12-11 |
| glipizide and metformin hydrochloride glipizide and metformin hydrochloride | ANDA | 2024-12-04 |
| glipizide and metformin hcl | ANDA | 2025-05-22 |
Show 41 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
EMPAGLIFLOZIN / METFORMIN HYDROCHLORIDE, SYNJARDY, BOEHRINGER INGELHEIM | |||
| 2026-12-20 | PED | ||
| 2026-06-20 | NPP | ||
EMPAGLIFLOZIN / METFORMIN HYDROCHLORIDE, SYNJARDY XR, BOEHRINGER INGELHEIM | |||
| 2026-12-20 | PED | ||
| 2026-06-20 | M-296 | ||
LINAGLIPTIN / METFORMIN HYDROCHLORIDE, JENTADUETO, BOEHRINGER INGELHEIM | |||
| 2026-12-20 | PED | ||
| 2026-06-20 | M-295 | ||
| 2023-03-30 | M-252 | ||
LINAGLIPTIN / METFORMIN HYDROCHLORIDE, JENTADUETO XR, BOEHRINGER INGELHEIM | |||
| 2026-12-20 | PED | ||
| 2026-06-20 | M-295 | ||
| 2023-03-30 | M-252 | ||
ERTUGLIFLOZIN / METFORMIN HYDROCHLORIDE, SEGLUROMET, MSD SUB MERCK | |||
| 2024-09-17 | M-275 | ||
METFORMIN HYDROCHLORIDE / SITAGLIPTIN PHOSPHATE, JANUMET, MSD SUB MERCK | |||
| 2024-06-04 | PED | ||
| 2023-12-04 | M-187 | ||
| 2023-02-12 | PED | ||
METFORMIN HYDROCHLORIDE / SITAGLIPTIN PHOSPHATE, JANUMET XR, MERCK SHARP DOHME | |||
| 2024-06-04 | PED | ||
| 2023-12-04 | M-187 | ||
| 2023-02-12 | PED | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Metformin Hydrochloride, Riomet Er, Sun Pharm | |||
| 9962336 | 2035-05-01 | DP | |
| Empagliflozin / Linagliptin / Metformin Hydrochloride, Trijardy Xr, Boehringer Ingelheim | |||
| 9949998 | 2034-06-11 | U-2290, U-2731 | |
| 10258637 | 2034-04-03 | U-2290, U-2731 | |
| 11090323 | 2034-04-03 | U-3192, U-3193 | |
| 10596120 | 2032-03-07 | DP | U-2775, U-2776, U-2790, U-2792 |
| 11564886 | 2032-03-07 | DP | U-3531 |
| 10406172 | 2030-06-15 | DP | U-2733 |
| 9155705 | 2030-05-21 | DP | |
| 8551957 | 2029-10-14 | DP | U-2730 |
| 9415016 | 2029-04-02 | DP | |
| 10022379 | 2029-04-02 | U-2339, U-2732 | |
| 7579449 | 2028-08-01 | DP | |
| 7713938 | 2027-04-15 | DS, DP | |
| 8883805 | 2025-11-26 | DP | |
| 7407955 | 2025-05-02 | DS, DP | |
| 8119648 | 2023-08-12 | U-802, U-1652 | |
| 8178541 | 2023-08-12 | DP | U-775, U-1652, U-1853 |
| Empagliflozin / Metformin Hydrochloride, Synjardy, Boehringer Ingelheim | |||
| 9949997 | 2034-05-17 | U-3532, U-3533 | |
| 10610489 | 2030-09-30 | DP | |
| Linagliptin / Metformin Hydrochloride, Jentadueto Xr, Boehringer Ingelheim | |||
| 9555001 | 2033-03-06 | DP | U-1967, U-1968 |
| 9173859 | 2027-05-04 | DP | U-1503 |
| Dapagliflozin / Metformin Hydrochloride, Xigduo Xr, Astrazeneca Ab | |||
| 9616028 | 2030-11-12 | DP | |
| 8685934 | 2030-05-26 | U-1522 | |
| 7919598 | 2029-12-16 | DP | |
| 8501698 | 2027-06-20 | DP | U-493 |
| 6515117 | 2025-10-04 | DS, DP | U-493 |
| Ertugliflozin / Metformin Hydrochloride, Segluromet, Msd Sub Merck | |||
| 9308204 | 2030-10-21 | DP | |
| 9439902 | 2030-10-21 | U-2214 | |
| 8080580 | 2030-07-13 | DS, DP | U-2214 |
| Canagliflozin / Metformin Hydrochloride, Invokamet, Janssen Pharms | |||
| 11576894 | 2030-07-06 | DP | |
| 7943582 | 2029-02-26 | DS, DP | U-493, U-2441, U-2632 |
| 8513202 | 2027-12-03 | DS, DP | U-493, U-2441, U-2632 |
| 7943788 | 2027-07-14 | DS, DP | |
| 8222219 | 2025-04-11 | U-493, U-2441, U-2632 | |
| 8785403 | 2024-07-30 | DP | |
| Linagliptin / Metformin Hydrochloride, Jentadueto, Boehringer Ingelheim | |||
| 8846695 | 2030-06-04 | U-1503 | |
| 10973827 | 2029-04-02 | DP | |
| 8673927 | 2027-05-04 | U-1503 | |
| Alogliptin Benzoate / Metformin Hydrochloride, Kazano, Takeda Pharms Usa | |||
| 8900638 | 2029-05-24 | DP | |
| 7807689 | 2028-06-27 | DS, DP | U-1337 |
| 8288539 | 2025-06-24 | DP | |
| 8173663 | 2025-03-15 | U-1338 | |
| Metformin Hydrochloride / Pioglitazone Hydrochloride, Actoplus Met, Takeda Pharms Usa | |||
| 9320714 | 2029-02-03 | DP | |
| 9101660 | 2027-01-22 | DP | |
Show 5 more
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BA: Biguanide blood glucose lower drugs
— A10BA02: Metformin
— A10BD: Combinations of oral blood glucose lowering drugs
— A10BD02: Metformin and sulfonylureas
— A10BD03: Metformin and rosiglitazone
— A10BD05: Metformin and pioglitazone
— A10BD07: Metformin and sitagliptin
— A10BD08: Metformin and vildagliptin
— A10BD10: Metformin and saxagliptin
— A10BD11: Metformin and linagliptin
— A10BD13: Metformin and alogliptin
— A10BD14: Metformin and repaglinide
— A10BD15: Metformin and dapagliflozin
— A10BD16: Metformin and canagliflozin
— A10BD17: Metformin and acarbose
— A10BD18: Metformin and gemigliptin
— A10BD20: Metformin and empagliflozin
— A10BD22: Metformin and evogliptin
— A10BD23: Metformin and ertugliflozin
— A10BD25: Metformin, saxagliptin and dapagliflozin
— A10BD26: Metformin and lobeglitazone
— A10BD27: Metformin, linagliptin and empagliflozin
HCPCS
No data
Clinical
Clinical Trials
2943 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 159 | 234 | 509 | 324 | 233 | 1421 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 81 | 164 | 333 | 175 | 152 | 876 |
| Healthy volunteers/patients | — | — | — | 205 | 2 | — | 2 | 13 | 222 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 16 | 24 | 35 | 47 | 60 | 170 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | 12 | 31 | 31 | 46 | 38 | 150 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 13 | 29 | 16 | 40 | 43 | 135 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | 6 | 10 | 11 | 18 | 39 | 81 |
| Syndrome | D013577 | — | — | 4 | 13 | 13 | 16 | 29 | 71 |
| Gestational diabetes | D016640 | — | O24.4 | 3 | 7 | 18 | 14 | 27 | 65 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | 4 | 6 | 6 | 14 | 28 | 56 |
Show 185 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 14 | 8 | 2 | — | 4 | 27 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 4 | 11 | 4 | — | 3 | 19 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 13 | 1 | — | 1 | 15 |
| Colorectal neoplasms | D015179 | — | — | 1 | 10 | 2 | — | 1 | 14 |
| Carcinoma | D002277 | — | C80.0 | 3 | 8 | 1 | — | 1 | 12 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | 6 | 4 | — | 2 | 11 |
| Covid-19 | D000086382 | — | U07.1 | — | 2 | 4 | — | 2 | 8 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 5 | 2 | — | — | 8 |
| Recurrence | D012008 | — | — | 3 | 1 | 1 | — | 2 | 7 |
| Hypercholesterolemia | D006937 | — | — | — | 2 | 2 | — | 2 | 6 |
Show 88 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 7 | 11 | — | — | 4 | 20 |
| Adenocarcinoma | D000230 | — | — | 1 | 10 | — | — | 1 | 12 |
| Lung neoplasms | D008175 | — | C34.90 | 2 | 9 | — | — | 1 | 12 |
| Melanoma | D008545 | — | — | 3 | 7 | — | — | — | 8 |
| Glioblastoma | D005909 | EFO_0000515 | — | 2 | 6 | — | — | — | 8 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 3 | 4 | — | — | 1 | 7 |
| Squamous cell carcinoma | D002294 | — | — | 3 | 4 | — | — | 1 | 7 |
| Lymphoma | D008223 | — | C85.9 | 2 | 4 | — | — | 1 | 7 |
| Pharmacokinetics | D010599 | — | — | 5 | 1 | — | — | 1 | 7 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 1 | — | — | 4 | 6 |
Show 157 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | 10 | — | — | — | 2 | 12 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 4 | — | — | — | 2 | 6 |
| Drug interactions | D004347 | — | — | 5 | — | — | — | — | 5 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | 3 | 4 |
| Lymphoid leukemia | D007945 | — | C91 | 2 | — | — | — | 2 | 4 |
| Microbiota | D064307 | — | — | 1 | — | — | — | 2 | 3 |
| Muscular atrophy | D009133 | — | — | 3 | — | — | — | — | 3 |
| Disease | D004194 | EFO_0000408 | R69 | 1 | — | — | — | 2 | 3 |
| Bronchopulmonary dysplasia | D001997 | — | P27.8 | 1 | — | — | — | 1 | 2 |
| Diabetes insipidus | D003919 | — | E23.2 | 1 | — | — | — | 1 | 2 |
Show 56 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatitis | D010195 | EFO_0000278 | K85 | — | — | — | — | 5 | 5 |
| Acidosis | D000138 | EFO_1000014 | E87.2 | — | — | — | — | 3 | 3 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | — | — | 2 | 2 |
| Disease-free survival | D018572 | EFO_0000409 | — | — | — | — | — | 2 | 2 |
| Ischemic stroke | D000083242 | — | — | — | — | — | — | 2 | 2 |
| Fertilization in vitro | D005307 | — | — | — | — | — | — | 2 | 2 |
| Body weight changes | D001836 | — | — | — | — | — | — | 2 | 2 |
| Essential hypertension | D000075222 | — | I10 | — | — | — | — | 2 | 2 |
| Intermittent fasting | D000093763 | — | — | — | — | — | — | 2 | 2 |
| Precocious puberty | D011629 | — | E22.8 | — | — | — | — | 2 | 2 |
Show 90 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Metformin |
| INN | metformin |
| Description | Metformin is a member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1. It has a role as a hypoglycemic agent, a xenobiotic, an environmental contaminant and a geroprotector. It is functionally related to a biguanide. It is a conjugate base of a metformin(1+). |
| Classification | Small molecule |
| Drug class | hypoglycemics (phenformin type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)C(=N)NC(=N)N |
Identifiers
| PDB | — |
| CAS-ID | 657-24-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1431 |
| ChEBI ID | 6801 |
| PubChem CID | 4091 |
| DrugBank | DB00331 |
| UNII ID | 9100L32L2N (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SLC47A1
SLC47A1
SLC47A2
SLC47A2
Organism
Homo sapiens
Gene name
SLC47A1
Gene synonyms
MATE1
NCBI Gene ID
Protein name
multidrug and toxin extrusion protein 1
Protein synonyms
hMATE-1, MATE-1, multidrug and toxin extrusion 1, solute carrier family 47 (multidrug and toxin extrusion), member 1, Solute carrier family 47 member 1
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Janumet – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Metformin – Amneal Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Metformin
+
Empagliflozin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Metformin
+
Glipizide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Metformin
+
Glyburide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Metformin
+
Linagliptin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Metformin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Metformin
+
Pioglitazone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Metformin
+
Rosiglitazone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Metformin
+
Saxagliptin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Metformin
+
Sitagliptin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 35,733 documents
View more details
Safety
Black-box Warning
Black-box warning for: Actoplus met, Alogliptin and metformin hydrochloride, Appformin, Appformin-d, Avandamet, Dapagliflozin and metformin hydrochloride, Fortamet, Glumetza, Glyburide and metformin hydrochloride, Glyburide-metformin hydrochloride, Invokamet, Invokamet invokamet xr, Janumet, Jentadueto, Jentadueto xr, Kazano, Kombiglyze, Metformin, Metformin er 500 mg metformin er 750 mg, Metformin hydrochloride, Metformin hydrochloride extended-release, Metformin hydrochloride metformin hydrochloride, Metformin hydrochloride oral solution, Pioglitazole and metformin hydrochloride, Pioglitazone and metformin, Pioglitazone hcl and metformin hcl, Pioglitazone hydrochloride and metformin hydrochloride, Saxagliptin and metformin, Saxagliptin and metformin hydrochloride, Segluromet, Sitagliptin and metformin hydrochloride, Synjardy, Synjardy synjardy, Trijardy xr, Xigduo, Zituvimet, Zituvimet xr
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
135,637 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use